Results 61 to 70 of about 1,881,376 (382)

Coupling of HIV-1 gp120-derived Core Protein to Paramagnetic Beads and Adsorption Assays

Bio-Protocol, 2015
Analysis of the functional activity in polyclonal serum following immunization of a complex protein or glycoprotein immunogen is a very important but tedious process.
Jidnyasa Ingale, Richard Wyatt
doaj   +1 more source

Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines

Cell Reports, 2020
Summary: Rational immunogen design aims to focus antibody responses to vulnerable sites on primary antigens. Given the size of these antigens, there is, however, potential for eliciting unwanted, off-target responses. Here, we use our electron microscopy
Bartek Nogal, Matteo Bianchi, Christopher A. Cottrell, Robert N. Kirchdoerfer, Leigh M. Sewall, Hannah L. Turner, Fangzhu Zhao, Devin Sok, Dennis R. Burton, Lars Hangartner, Andrew B. Ward   +10 more
doaj   +1 more source

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge [PDF]

, 2016
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation the liver graft of viremic patients universally becomes infected by circulating virus ...
Baumert, Thomas F., Cole, Sarah, Desombere, Isabelle, Fafi-Kremer, Samira, Farhoudi, Ali, Heydmann, Laura, Leroux-Roels, Geert, McKeating, Jane A., Meuleman, Philip, Patel, Arvind H., Pessaux, Patrick, Van Houtte, Freya, Verhoye, Lieven   +12 more
core   +3 more sources

Use of Transient Transfection for cGMP Manufacturing of eOD-GT8 60mer, a Self-Assembling Nanoparticle Germline-Targeting HIV-1 Vaccine Candidate

Pharmaceutics
We describe the current Good Manufacturing Practice (cGMP) production and subsequent characterization of eOD-GT8 60mer, a glycosylated self-assembling nanoparticle HIV-1 vaccine candidate and germline targeting priming immunogen.
Vaneet K. Sharma, Sergey Menis, Evan T. Brower, Eddy Sayeed, Jim Ackland, Angela Lombardo, Christopher A. Cottrell, Jonathan L. Torres, Thomas Hassell, Andrew B. Ward, Vadim Tsvetnitsky, William R. Schief   +11 more
doaj   +1 more source

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. [PDF]

PLoS Pathogens, 2007
Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect ...
Wendelien B Oswald, Thomas W Geisbert, Kelly J Davis, Joan B Geisbert, Nancy J Sullivan, Peter B Jahrling, Paul W H I Parren, Dennis R Burton   +7 more
doaj   +1 more source

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Nature Communications, 2020
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine ...
Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, M. Garcia-Blanco, Vineet D. Menachery, Xuping Xie, P. Shi   +6 more
semanticscholar   +2 more sources

An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion

Bone Research, 2021
Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures.
Gehua Zhen, Yang Dan, Ruomei Wang, Ce Dou, Qiaoyue Guo, Melissa Zarr, Linda N. Liu, Lieping Chen, Ruoxian Deng, Yusheng Li, Zengwu Shao, Xu Cao   +11 more
doaj   +1 more source

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA, Montefiori D.C., Pabst M., Pegu A., WHO   +4 more
core   +1 more source

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

Nature Communications, 2019
Stabilized, native-like trimers of the HIV envelope protein, such as SOSIP trimers, are potential antigens for an HIV vaccine. Here, the authors generate a SOSIP trimer based on the consensus sequence of group M isolates, determine its structure and ...
Kwinten Sliepen, Byung Woo Han, Ilja Bontjer, Petra Mooij, Fernando Garces, Anna-Janina Behrens, Kimmo Rantalainen, Sonu Kumar, Anita Sarkar, Philip J. M. Brouwer, Yuanzi Hua, Monica Tolazzi, Edith Schermer, Jonathan L. Torres, Gabriel Ozorowski, Patricia van der Woude, Alba Torrents de la Peña, Mariëlle J. van Breemen, Juan Miguel Camacho-Sánchez, Judith A. Burger, Max Medina-Ramírez, Nuria González, Jose Alcami, Celia LaBranche, Gabriella Scarlatti, Marit J. van Gils, Max Crispin, David C. Montefiori, Andrew B. Ward, Gerrit Koopman, John P. Moore, Robin J. Shattock, Willy M. Bogers, Ian A. Wilson, Rogier W. Sanders   +34 more
doaj   +1 more source

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection [PDF]

Current Opinion in HIV and AIDS, 2014
Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
Cynthia A, Derdeyn, Penny L, Moore, Lynn, Morris   +2 more
openaire   +2 more sources